Pfizer Inc PFE
We take great care to ensure that the data presented and summarized in this overview for PFIZER INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PFE
View all-
Vanguard Group Inc Valley Forge, PA511MShares$14 Billion0.28% of portfolio
-
Black Rock Inc. New York, NY424MShares$11.7 Billion0.27% of portfolio
-
State Street Corp Boston, MA287MShares$7.88 Billion0.36% of portfolio
-
Wellington Management Group LLP Boston, MA166MShares$4.57 Billion0.85% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA117MShares$3.22 Billion0.63% of portfolio
-
Geode Capital Management, LLC Boston, MA116MShares$3.18 Billion0.29% of portfolio
-
Capital World Investors Los Angeles, CA88.1MShares$2.42 Billion0.41% of portfolio
-
Norges Bank Oslo, Q884MShares$2.31 Billion0.36% of portfolio
-
Morgan Stanley New York, NY77.5MShares$2.13 Billion0.17% of portfolio
-
Massachusetts Financial Services CO Boston, MA71.8MShares$1.97 Billion0.64% of portfolio
Latest Institutional Activity in PFE
Top Purchases
Top Sells
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Transactions at PFE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 30
2024
|
Scott Gottlieb Director |
BUY
Open market or private purchase
|
Direct |
1,000
+9.09%
|
$28,000
$28.24 P/Share
|
Aug 31
2024
|
Aamir Malik Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
20,195
-40.6%
|
$585,655
$29.01 P/Share
|
Aug 13
2024
|
Jennifer B. Damico SVP & Controller |
SELL
Open market or private sale
|
Direct |
5,154
-37.52%
|
$144,312
$28.66 P/Share
|
May 31
2024
|
David M Denton Chief Financial Officer & EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
12,107
-24.2%
|
$338,996
$28.66 P/Share
|
Feb 28
2024
|
Christoffel Boshoff Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
4,150
-2.59%
|
$112,050
$27.04 P/Share
|
Feb 28
2024
|
Christoffel Boshoff Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
11,510
+6.7%
|
-
|
Feb 28
2024
|
Mikael Dolsten President R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
21,437
-6.25%
|
$578,799
$27.04 P/Share
|
Feb 27
2024
|
Alexandre De Germay Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
74,377
+50.0%
|
-
|
Feb 27
2024
|
Jennifer B. Damico SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
5,113
+27.48%
|
-
|
Feb 26
2024
|
Michael Mc Dermott Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,063
-7.44%
|
$163,701
$27.18 P/Share
|
Feb 25
2024
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,386
-14.19%
|
$37,422
$27.76 P/Share
|
Feb 25
2024
|
Michael Mc Dermott Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,992
-3.54%
|
$80,784
$27.76 P/Share
|
Feb 25
2024
|
Christoffel Boshoff Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,197
-2.02%
|
$167,319
$27.76 P/Share
|
Feb 25
2024
|
Christoffel Boshoff Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
15,455
+9.08%
|
-
|
Feb 24
2024
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
354
-3.5%
|
$9,558
$27.76 P/Share
|
Feb 24
2024
|
Christoffel Boshoff Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
300
-0.21%
|
$8,100
$27.76 P/Share
|
Feb 23
2024
|
Albert Bourla Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
112,009
-12.98%
|
$3,024,243
$27.57 P/Share
|
Feb 23
2024
|
Albert Bourla Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
127,674
+22.5%
|
$3,447,198
$27.34 P/Share
|
Feb 23
2024
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
9,106
-16.75%
|
$245,862
$27.63 P/Share
|
Feb 23
2024
|
Jennifer B. Damico SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
9,752
+33.65%
|
$263,304
$27.34 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 360K shares |
---|---|
Grant, award, or other acquisition | 141K shares |
Open market or private purchase | 4K shares |
Payment of exercise price or tax liability | 418K shares |
---|---|
Open market or private sale | 5.15K shares |